Atrial fibrillation (AF) represents the arrhythmia of greatest clinical impact and catheter ablation of AF (CAAF) has become the most effective strategy for rhythm control in selected patients. Therefore, appropriate anticoagulation strategies are of paramount importance for patients undergoing CAAF, especially those at high risk, such those with high CHA2DS2VASc scores. Optimal management of anticoagulation before, during, and after CAAF is crucial. Several studies have evaluated the use of different anticoagulation strategies in the periprocedural period. Randomized controlled trial seem to suggest that in patients undergoing CAAF, uninterrupted (or minimally interrupted) direct oral anticoagulants (DOACs) provides an alternative to continuous vitamin K antagonists strategy, with low thromboembolic and bleeding risk.

Giuseppe Coppola, E.C. (2021). Direct Oral Anticoagulants in the Setting of Catheter Ablation of Atrial Fibrillation: State of art. CURRENT PROBLEMS IN CARDIOLOGY, 46(3) [10.1016/j.cpcardiol.2020.100622].

Direct Oral Anticoagulants in the Setting of Catheter Ablation of Atrial Fibrillation: State of art

Giuseppe Coppola;Egle Corrado;Girolamo Manno
;
Antonino Mignano;
2021-01-01

Abstract

Atrial fibrillation (AF) represents the arrhythmia of greatest clinical impact and catheter ablation of AF (CAAF) has become the most effective strategy for rhythm control in selected patients. Therefore, appropriate anticoagulation strategies are of paramount importance for patients undergoing CAAF, especially those at high risk, such those with high CHA2DS2VASc scores. Optimal management of anticoagulation before, during, and after CAAF is crucial. Several studies have evaluated the use of different anticoagulation strategies in the periprocedural period. Randomized controlled trial seem to suggest that in patients undergoing CAAF, uninterrupted (or minimally interrupted) direct oral anticoagulants (DOACs) provides an alternative to continuous vitamin K antagonists strategy, with low thromboembolic and bleeding risk.
2021
Settore MED/11 - Malattie Dell'Apparato Cardiovascolare
Giuseppe Coppola, E.C. (2021). Direct Oral Anticoagulants in the Setting of Catheter Ablation of Atrial Fibrillation: State of art. CURRENT PROBLEMS IN CARDIOLOGY, 46(3) [10.1016/j.cpcardiol.2020.100622].
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0146280620300992-main.pdf

Solo gestori archvio

Tipologia: Post-print
Dimensione 462.79 kB
Formato Adobe PDF
462.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/544500
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact